Literature DB >> 29997994

Lung adenocarcinoma patient with an EGFR kinase domain duplication (KDD) and the response to icotinib.

You-Cai Zhu1, Wen-Xian Wang2, Chun-Wei Xu3, Qing-He Tan4, Jian-Ying Li4, Wu Zhuang5, Zheng-Bo Song2, Kai-Qi Du1, Gang Chen3, Tang-Feng Lv6, Yong Song6.   

Abstract

Entities:  

Year:  2018        PMID： 29997994      PMCID： PMC6006119          DOI： 10.21037/jtd.2018.04.162

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  16 in total

1.  Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication.

Authors:  Christina S Baik; David Wu; Christina Smith; Renato G Martins; Colin C Pritchard
Journal:  J Thorac Oncol       Date:  2015-10       Impact factor: 15.609

2.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Authors:  Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2012-01-26       Impact factor: 41.316

3.  EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.

Authors:  Kartik Konduri; Jean-Nicolas Gallant; Young Kwang Chae; Francis J Giles; Barbara J Gitlitz; Kyle Gowen; Eiki Ichihara; Taofeek K Owonikoko; Vijay Peddareddigari; Suresh S Ramalingam; Satyanarayan K Reddy; Beth Eaby-Sandy; Tiziana Vavalà; Andrew Whiteley; Heidi Chen; Yingjun Yan; Jonathan H Sheehan; Jens Meiler; Deborah Morosini; Jeffrey S Ross; Philip J Stephens; Vincent A Miller; Siraj M Ali; Christine M Lovly
Journal:  Cancer Discov       Date:  2016-04-21       Impact factor: 39.397

4.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

5.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

Review 6.  New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer.

Authors:  Geoffrey R Oxnard; Maria E Arcila; Juliann Chmielecki; Marc Ladanyi; Vincent A Miller; William Pao
Journal:  Clin Cancer Res       Date:  2011-07-20       Impact factor: 12.531

7.  EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.

Authors:  Jean-Nicolas Gallant; Jonathan H Sheehan; Timothy M Shaver; Mark Bailey; Doron Lipson; Raghu Chandramohan; Monica Red Brewer; Sally J York; Mark G Kris; Jennifer A Pietenpol; Marc Ladanyi; Vincent A Miller; Siraj M Ali; Jens Meiler; Christine M Lovly
Journal:  Cancer Discov       Date:  2015-08-18       Impact factor: 39.397

8.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

9.  Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer.

Authors:  Kajsa Ericson Lindquist; Anna Karlsson; Per Levéen; Hans Brunnström; Christel Reuterswärd; Karolina Holm; Mats Jönsson; Karin Annersten; Frida Rosengren; Karin Jirström; Jaroslaw Kosieradzki; Lars Ek; Åke Borg; Maria Planck; Göran Jönsson; Johan Staaf
Journal:  Oncotarget       Date:  2017-05-23

Review 10.  The resistance mechanisms and treatment strategies for EGFR-mutant advanced non-small-cell lung cancer.

Authors:  Wen-Zhao Zhong; Qing Zhou; Yi-Long Wu
Journal:  Oncotarget       Date:  2017-08-17
View more
  6 in total

1.  Role of the EGFR-KDD mutation as a possible mechanism of acquired resistance of non-small cell lung cancer to EGFR tyrosine kinase inhibitors: A case report.

Authors:  Cheng He; Yong Wang
Journal:  Mol Clin Oncol       Date:  2021-12-10

2.  The landscape of kinase domain duplication in Chinese lung cancer patients.

Authors:  Di Wu; Yuancai Xie; Chang'e Jin; Jinfan Qiu; Ting Hou; Haiwei Du; Songan Chen; Jianxing Xiang; Xi Shi; Junling Liu
Journal:  Ann Transl Med       Date:  2020-12

3.  Lung Adenocarcinoma Harboring EGFR Kinase Domain Duplication (EGFR-KDD) Confers Sensitivity to Osimertinib and Nivolumab: A Case Report.

Authors:  Jie Li; Junrong Yan; Ran Cao; Guanjun Du; Guofang Zhao
Journal:  Front Oncol       Date:  2020-12-17       Impact factor: 6.244

4.  Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations.

Authors:  Teng Li; Shouzheng Wang; Jianming Ying; Yan Wang; Xingsheng Hu; Xuezhi Hao; Ziyi Xu; Puyuan Xing; Junling Li
Journal:  Thorac Cancer       Date:  2021-09-21       Impact factor: 3.500

5.  Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non-Small Cell Lung Cancer.

Authors:  Chaelin Lee; Miso Kim; Dong-Wan Kim; Tae Min Kim; Soyeon Kim; Sun-Wha Im; Yoon Kyung Jeon; Bhumsuk Keam; Ja-Lok Ku; Dae Seog Heo
Journal:  Cancer Res Treat       Date:  2021-05-03       Impact factor: 4.679

6.  Durable response to EGFR tyrosine kinase inhibitors in a patient with non-small cell lung cancer harboring an EGFR kinase domain duplication.

Authors:  Esuteru Hirokawa; Satomi Watanabe; Kazuko Sakai; Masayuki Takeda; Chihiro Sato; Takayuki Takahama; Kazuto Nishio; Kazuhiko Nakagawa
Journal:  Thorac Cancer       Date:  2021-07-09       Impact factor: 3.500
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.